- Fluidigm, a small-cap diagnostics company, surged as much as 42% on Wednesday after the FDA granted its COVID-19 saliva test emergency authorization.
- Fluidigm’s COVID-19 saliva test allows patients to avoid the more invasive nasal swab that has primarily been used to detect COVID-19 in a patient.
- According to Fluidigm, its saliva-based COVID-19 test “demonstrated 100 percent agreement” between the saliva results from the assay and the results from paired nasal swab samples tested with authorized assays.
- Andrew Left of Citron Research tweeted that Fluidigm will “change COVID-19 testing forever,” adding that its stock is poised to surge 314% from its Tuesday close to $35.
- Visit the Business Insider homepage for more stories.
Fluidigm might be the company to finally offer an alternative to the painful nasal swabs used to test patients for COVID-19.
On Wednesday, the California-based small-cap diagnostics company received FDA emergency authorization for its COVID-19 saliva test.
The company demonstrated that 100% of its saliva-based tests matched the results of nasal swabs in a clinical study, according to a press release.
Fluidigm said the saliva test for COVID-19 will be available for immediate shipment, and each diagnostic system used to analyze samples will have a capacity of up to 6,000 tests per day.
The arrival of a new COVID-19 test that is minimally invasive and produces rapid test results has the potential to change the dynamic of the testing landscape in the US, which has been bogged down by delayed test results and unwillingness of some to get tested due to the invasive nature of the nasal swab.
Read more: David Baron’s fund has returned 400% to investors in the last decade using 20 stocks or less. He shared with us the 3 stocks he snapped up in 2020 – and the 3 travel and entertainment bets he loves going forward.
One hedge fund manager that sees potential in Fluidigm is Andrew Left of Citron Research.
In a tweet on Wednesday, Left said he thinks Fluidigm could surge 314% from Tuesday’s close to $35 due to the FDA’s emergency authorization decision.
“Company [Fluidigm] will change COVID-19 testing forever as their saliva-based test Demonstrated 100 Percent Agreement with Nasopharyngeal Assays,” Left said, adding that Fluidigm has a “real product and management” team.
Shares of Fluidigm surged as much as 42% to $12.45 in Wednesday trades.